Introduction {#S0001}
============

Cancer cachexia, also known as cancer-related wasting syndrome and cancer anorexia-cachexia syndrome, is a multifactorial syndrome defined by an ongoing loss of skeletal muscle mass, with or without loss of fat mass, that cannot be fully reversed by conventional nutritional support, leading to progressive functional impairment.[@CIT0001] It is also an indicator of tumor progression in patients with malignancy.[@CIT0002] Recently, cachexia has been receiving increasing attention because of its high prevalence, affecting nearly 50--80% of cancer patients, depending on the tumor type.[@CIT0003] Further, it may be the leading cause of nearly 20% of cancer deaths.[@CIT0003],[@CIT0004]

The inability to prevent weight loss through nutritional intervention is one of several important distinctions between cancer cachexia and simple starvation.[@CIT0001] Moreover, the co-occurrence of cancer, especially gastrointestinal cancer, and cachexia greatly weakens the patient's ability to recover. Bachmann et al demonstrated that pancreatic cancer patients with cachexia experienced a greater decline in survival,[@CIT0005] and Fukuta et al reported that preoperative cachexia greatly increased the postoperative length of stay in elderly patients with gastrointestinal cancer.[@CIT0006] Another report stated that the risk of inpatient death was higher for gastric cancer (GC) patients with cachexia.[@CIT0007] However, few studies have focused on the impact of cachexia on the long-term survival of GC patients, and most such studies only examined elderly patients.

Therefore, the relationship between GC and cachexia still needs to be fully elucidated to develop effective therapeutic strategies that consider this relationship. This study aimed to comprehensively evaluate the potential prognostic utility of cachexia in GC patients, including examining the differences between younger and elderly patients.

Materials and methods {#S0002}
=====================

Patients {#S0002-S2001}
--------

Data were prospectively collected from 578 patients with GC who underwent subtotal gastrectomy at the Gastrointestinal Surgical Departments of The Second Affiliated Hospital of Wenzhou Medical University and The First Affiliated Hospital of Wenzhou Medical University in China between January 2014 and December 2016. Three patients who lacked imaging data were excluded. Current study was carried out in accordance with the Declaration of Helsinki, and the study protocol was approved by the ethics committees of the Second Affiliated Hospital of Wenzhou Medical University and the First Affiliated Hospital of Wenzhou Medical University.

Diagnosis of cancer cachexia {#S0002-S2002}
----------------------------

The definition of cachexia was \>5% loss of stable body weight over the previous 6 months, a body mass index (BMI) \<20 kg/m2 and ongoing weight loss \>2%, or sarcopenia and ongoing weight loss \>2%.[@CIT0001] Specifically, low muscle mass was defined as a skeletal muscle mass index of \<7 kg/m2 for men and \<5.7 kg/m2 for women.[@CIT0006] Muscle mass was assessed using multifrequency bioelectrical impedance with eight tactile electrodes (InBody 430; Inbody Japan, Tokyo, Japan).

Statistical analysis {#S0002-S2003}
--------------------

The Kolmogorov--Smirnov test was performed to assess the distribution equality of continuous parameters. Normally distributed data are presented as means ± standard deviations (SDs), and non-normally distributed data are presented as medians and interquartile ranges (IQRs). In univariate analyses, the independent *t*-test and Mann--Whitney U-test were used to analyze intergroup differences in continuous variables, and the chi-square test and Fisher's exact test were applied to categorical variables. Overall survival (OS) was defined as the time between the date of diagnosis and the date of death or last known follow-up. The Kaplan--Meier method and log-rank test were used to estimate and compare survival based on specific factors. The Cox proportional hazard model was used to estimate the risk ratio in univariate and multivariate analyses. All *P*-values were two-sided, and *P*\<0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (version 22.0; SPSS Inc., Chicago, IL, USA).

Results {#S0003}
=======

Patient characteristics {#S0003-S2001}
-----------------------

A total of 575 patients were enrolled in the present study. The baseline characteristics of these patients are shown in [Table 1](#T0001){ref-type="table"}. Most patients were men (n=433, 75.3%), and the mean age of all the patients was 64.41 years (SD =10.6). The median BMI was 22.21 kg/m2 (IQR =20.20--24.22). The mean PLR (platelet/lymphocyte ratio) and NLR (neutrophil/lymphocyte ratio) were 169.87 (SD =10.6) and 2.71 (SD =2.0), respectively. Of the 575 patients analyzed, 206 (35.8%) were diagnosed with cancer cachexia.Table 1Demographics, patient characteristics in overall study population and by cachexia groupFactorsTotal (n=575)Non-cachexia (n=369)Cachexia (n=206)*P*-valueGender0.668 Male433 (75.3%)280 (75.9%)153 (74.3%) Female142 (24.7%)89 (24.1%)53 (25.7%)Age (y)64.41±10.663.24±10.466.49±10.8\<0.001\*BMI (kg/m2)22.21 (20.20---24.22)22.50 (20.57---24.61)21.51 (19.54---23.7)\<0.001\*PLR169.87±95.8159.94±92.1187.70±99.90.001\*NLR2.71±2.02.56±1.63.17±2.5\<0.001\*Skeletal muscle (cm2)41.98 (35.86---47.93)42.92 (37.45---48.90)39.52 (34.43---46.99)\<0.001\*Grip strength (kg)28.90 (22.0---35.5)30.25 (23.4---41.1)26.00 (19.9---32.9)\<0.001\*Stride speed (m/s)1.00±0.20.99±0.20.96±0.30.246Preoperative hemoglobin120.83±22.0124.15±21.1114.87±22.5\<0.001\*Preoperative albumin38.50 (34.95---41.50)39.20 (35.70---41.90)37.20 (33.65---40.2)\<0.001\*ASA0.001\* 1--2475 (82.6%)319 (86.4%)156 (75.7%) 3--4100 (17.4%)50 (13.6%)50 (24.3%)Charison scroe\<0.001\* 0293 (51.0%)214 (58.0%)79 (38.3%) 1--3260 (45.2%)149 (40.4%)111 (53.9%) 4--622 (3.8%)6 (1.6%)16 (7.8%)Preoperative anaemia\<0.001\* No475 (82.6%)322 (87.3%)153 (74.3%) Yes100 (13.4%)47 (12.7%)53 (25.7%)Preoperative bleeding0.006\* No487 (84.7%)324 (87.8%)163 (79.1%) Yes88 (15.3%)45 (12.2%)43 (20.9%)Preoperative obstruction\<0.001\* No521 (90.6%)361 (97.8%)160 (77.7%) Yes54 (9.4%)8 (0.2%)46 (22.3%)Tumor location0.04\* Cardia73 (12.7%)39 (10.6%)34 (16.5%) Body116 (20.2%)77 (20.9%)39 (18.9%) Antrum364 (63.3%)243 (65.9%)121 (58.7%) Total22 (3.8%)10 (2.6%)12 (5.9%)Tumor size0.016\* ≤4.75372 (64.7%)252 (68.3%)120 (58.3%) \>4.75203 (35.3%)117 (31.7%)86 (41.7%)Histopathological differentiation0.091 Differentiated422 (73.4%)273 (74.0%)149 (72.3%) Undifferentiated51 (8.9%)26 (7.0%)25 (12.2%) Signet ring cell carcinoma102 (17.7%)70 (19.0%)32 (15.5%)Pathologic type\<0.001\* Ulcerative type504 (87.7%)337 (91.3%)167 (81.1%) Non-ulcerative type71 (12.3%)32 (8.7%)39 (18.9%)TNM stage\<0.001\* I185 (32.2%)145 (39.3%)40 (19.4%) II124 (21.6%)76 (20.6%)48 (23.3%) III266 (46.2%)148 (40.1%)118 (57.3%)Surgical bleeding0.066 No500 (87.0%)328 (88.9%)172 (83.5%) Yes75 (13.0%)41 (11.1%)34 (16.5%)Operation time0.673 ≤210min311 (54.1%)202 (54.7%)109 (52.9%) \>210min264 (45.9%)167 (45.3%)97 (47.1%)Abdominal surgery history0.38 No506 (88.0%)328 (88.9%)178 (86.4%) Yes69 (12.0%)41 (11.1%)28 (13.6%)Length of stay (d)15.77±9.3614.97±9.3917.19±9.170.006Total cost (yuán)64,297.95±30,643.8661,791.02±32,846.5868,788.52±25,709.930.009[^2][^3]

Correlation of clinicopathologic characteristics with cachexia {#S0003-S2002}
--------------------------------------------------------------

The chi-square test, independent *t*-test, and Mann--Whitney U-test were used to examine the relationship between clinical characteristics and cachexia. Age (*P*\<0.001), BMI (*P*\<0.001), PLR (*P*=0.001), NLR (*P*\<0.001), skeletal muscle mass (*P*\<0.001), grip strength (*P*\<0.001), preoperative hemoglobin (*P*\<0.001), preoperative albumin (*P*\<0.001), ASA (*P*\<0.001), Charlson comorbidity index (CCI) (*P*\<0.001), preoperative bleeding (*P*=0.006), preoperative obstruction (*P*\<0.001), tumor size (*P*=0.016), pathologic type (*P*\<0.001), and TNM stage (*P*\<0.001) were significantly correlated with cachexia. Further, the postoperative length of stay was longer, and the total hospitalization cost was higher in the cachexia group ([Table 1](#T0001){ref-type="table"}). There was no significant association between cachexia and gender, visceral fat area, stride speed, histopathological differentiation, surgical bleeding, or abdominal surgery history.

Cachexia was independently associated with worse OS in GC patients {#S0003-S2003}
------------------------------------------------------------------

As shown in [Figure 1](#F0001){ref-type="fig"}, patients with cachexia had a poor outcome: the median survival time in patients with cachexia (29.2 months) was shorter than in those without (35.7 months) (*P*\<0.001). On univariate analysis, cachexia was also associated with worse OS (hazard ratio \[HR\] 1.976, 95% confidence interval \[CI\] 1.471--2.653, *P*\<0.001). Additionally, age (HR 2.107, 95% CI 1.569--2.830, *P*\<0.001), lower BMI (HR 1.781, 95% CI 1.120--2.834, *P*=0.015), higher ASA stage (HR 1.654, 95% CI 1.173--2.332, *P*=0.004), higher CCI (CCI 1--3: HR 1.412, 95% CI 1.041--1.914, *P*=0.026; CCI 4--6: HR 2.133, 95% CI 1.103--4.126, *P*=0.024), lower preoperative grip strength (HR 1.858, 95% CI 1.365--2.530, *P*\<0.001), preoperative anemia (HR 1.520, 95% CI 1.072--2.155, *P*=0.019), preoperative hypoalbuminemia (HR 2.344, 95% CI 1.272--4.320, *P*=0.006), readmission (HR 1.940, 95% CI 1.218--3.089, *P*=0.005), larger tumor size (HR 2.830, 95% CI 2.102--3.810, *P*\<0.001), higher TNM stage (stage II: HR 2.747, 95% CI 1.480--5.098, *P*\<0.001; stage III: HR 7.823, 95% CI 4.654--13.149, *P*\<0.001), anastomotic method (Billroth II: HR 2.612, 95% CI 1.661--4.108, *P*\<0.001; Roux-en-Y: HR 2.909, 95% CI 2.004--4.224, *P*\<0.001), intraoperative blood transfusion (HR 2.844, 95% CI 1.833--4.411, *P*\<0.001), intraoperative bleeding (HR 2.835, 95% CI 1.813--4.434, *P*\<0.001), postoperative complications above grade 2 (HR 2.095, 95% CI 1.526--2.877, *P*\<0.001), and combined operation (HR 2.284, 95% CI 1.515--3.444, *P*\<0.001) were associated with poor OS. Furthermore, whole stomach cancer (HR 4.125, 95% CI 2.159--7.879, *P*\<0.001) and a higher NLR (HR 1.482, 95% CI 1.101--1.994, *P*=0.009) were also associated with worse OS ([Table 2](#T0002){ref-type="table"}). No other clinicopathologic factors were statistically linked to outcome. On multivariate analysis, cachexia (HR 1.456, 95% CI 1.070--1.981, *P*=0.017), age (HR 1.811, 95% CI 1.334--2.458, *P*\<0.001), readmission (HR 2.559, 95% CI 1.562--4.191, *P*\<0.001), tumor size (HR 1.639, 95% CI 1.187--2.261, *P*=0.003), TNM stage (stage II: HR 2.215, 95% CI 1.155--4.248, *P*=0.017; stage III: HR 5.758, 95% CI 3.285--10.094, *P*\<0.001), whole stomach cancer (HR 2.639, 95% CI 1.358--5.130, *P*\<0.001), and combined operation (HR 1.598, 95% CI 1.042--2.449, *P*=0.032) were independently associated with worse OS ([Table 2](#T0002){ref-type="table"}).Table 2COX regression analysis of the relationship between OS and cachexia or patient characteristicsFactorsUnivariateMultivariateHR (95% CI)*P*-valueHR (95% CI)*P*-valueGender MaleReference Female1.292 (0.899--1.856)0.166Age \<70ReferenceReference ≥702.107 (1.569--2.830)\<0.001\*1.811 (1.334--2.458)\<0.001\*BMI (kg/m2) 18.5---23.5Reference \<18.51.781 (1.120--2.834)0.015\* \>23.50.949 (0.686--1.313)0.752ASA 1--2Reference 3--41.654 (1.173--2.332)0.004\*Charison scroe 0Reference 1--31.412 (1.041--1.914)0.026\* 4--62.133 (1.103--4.126)0.024\*PLR ≤131.1Reference \>131.11.336 (0.978--1.825)0.068NLR ≤2.28Reference \>2.281.482 (1.101--1.994)0.009\*Preoperative Grip strength NormalReference Low1.858 (1.365--2.530)\<0.001\*Preoperative anemia NoReference Yes1.520 (1.072--2.155)0.019\*Preoperative hypoalbuminemia NoReference Yes2.344 (1.272--4.320)0.006\*Surgery history NoReference Yes1.275 (0.835--1.946)0.260Readmission NoReferenceReference Yes1.940 (1.218--3.089)0.005\*2.559 (1.562--4.191)\<0.001\*Cachexia NoReferenceReference Yes1.976 (1.471--2.653)\<0.001\*1.456 (1.070--1.981)0.017\*Tumor size ≤4.75ReferenceReference \>4.752.830 (2.102--3.810)\<0.001\*1.639 (1.187--2.261)0.003\*Histopathological differentiation DifferentiatedReference Undifferentiated1.519 (0.948--2.434)0.082Pathologic type Ulcerative typeReference Non-ulcerative type0.712 (0.473--1.073)0.105TNM stage IReferenceReference II2.747 (1.480--5.098)\<0.001\*2.215 (1.155--4.248)0.017\* III7.823 (4.654--13.149)\<0.001\*5.758 (3.285--10.094)\<0.001\*Tumor location CardiaReferenceReference Body0.940 (0.548--1.611)0.8211.044 (0.6--1.817)0.878 Antrum0.941 (0.594--1.489)0.7951.118 (0.697--1.793)0.643 Total4.125 (2.159--7.879)\<0.001\*2.639 (1.358--5.130)\<0.001\*Anastomotic method Billroth IReference Billroth II2.612 (1.661--4.108)\<0.001\* Roux-en-y2.909 (2.004--4.224)\<0.001\*Intraoperative blood transfusion NoReference Yes2.844 (1.833--4.411)\<0.001\*Intraoperative bleeding NoReference Yes2.835 (1.813--4.434)\<0.001\*Postoperative complications above grade 2 NoReference Yes2.095 (1.526--2.877)\<0.001\*Combined operation NoReferenceReference Yes2.284 (1.515--3.444)\<0.001\*1.598 (1.042--2.449)0.032\*[^4][^5] Figure 1Kaplan--Meier curve for overall survival (OS) in patients with and without cachexia.

Cachexia was associated with worse prognosis in younger patients {#S0003-S2004}
----------------------------------------------------------------

As shown in [Figure 2](#F0002){ref-type="fig"}, of the 575 GC patients, most patients were 50--80 years old. There were 29.4% (5/17), 27.8% (10/36), 34.1% (46/135), 28.3% (58/205), 45.7% (74/162), and 65.0% (13/20) of patients younger than 40, 41--50, 51--60, 61--70, 71--80 and older than 81 age groups, respectively, diagnosed with cachexia.Figure 2Frequency distribution of patients of different ages stratum with and without cachexia.

As only 17 patients were younger than 40 years old and 20 patients were older than 80 years old, we further subdivided the patients into 4 groups, namely, patients aged younger than 50 (group I), patients 51--60 years old (group II), patients 61--70 years old (group III), and patients older than 71 (group IV). Interestingly, cachexia was able to predict poor outcome in the younger patients. The median survival in patients with cachexia was statistically shorter than that in those without cachexia in group I (*P*=0.015), group II (*P*=0.022), and group III (*P*=0.029). Although the median survival was also shorter in cachexia patients in group IV, no statistical differences were found (*P*=0.117) ([Figure 3A](#F0003){ref-type="fig"}). Additionally, as shown in [Table 3](#T0003){ref-type="table"}, the effect of cachexia on prognosis decreased as age increased, and cachexia was a more effective risk factor for survival in group I (HR 4.947, 95% CI 1.181--20.727, *P*=0.029) than the other three groups (group II: HR 2.232, 95% CI 1.103--4.518, *P*=0.026; group III: HR 1.806, 95% CI 1.052--3.098, *P*=0.032; group IV: HR 1.411, 95% CI 0.915--2.174, *P*=0.119). Further, cachexia only significantly affected postoperative length of stay and hospitalization costs in group I; no such differences were found in the other three groups ([Figure 3B](#F0003){ref-type="fig"}).Table 3COX regression analysis of the relationship between OS and cachexia in patients with different agesGroupHR (95% CI)*P*-value≤50 y4.947 (1.181--20.727)0.029\*51--60 y2.232 (1.103--4.518)0.026\*61--70 y1.806 (1.052--3.098)0.032\*≥71 y1.411 (0.915--2.174)0.119[^6] Figure 3(**A**) Kaplan--Meier curve for overall survival (OS) in different ages stratum with and without cachexia. (**B**) Total cost and length of hospital stay in different ages stratum with and without cachexia.

Discussion {#S0004}
==========

Cancer cachexia is a multifactorial syndrome, primarily defined as a complex metabolic syndrome associated with underlying illness and characterized by loss of muscle.[@CIT0008] Historically, cachexia was thought of as a syndrome of anorexia, fatigue, and weight loss. However, it was recently redefined precisely as lean muscle mass loss associated with chronic illness and/or cancer.[@CIT0009] Using the corrected definition, the prevalence of cachexia was 35.8% in this prospective study. A previous study including patients with several cancer types investigated the association between cachexia and hospitalization costs in the United States, as well as length of stay, and found that the prevalence of cachexia in GC patients was 7.49%,[@CIT0007] much lower than that in our study. It is possible that the previous study did not use the consensus diagnostic criteria for cachexia. Further, ethnic differences may contribute bias to some extent.

The present study prospectively investigated the impact of preoperative cachexia on postoperative OS in GC patients. Our results demonstrated that OS was significantly shorter in patients with preoperative cachexia, and cachexia was found to be an independent risk factor of OS. The relationship between cachexia and disease outcome could probably be explained by the effects of inflammation and malnutrition. Previous studies have suggested a possible association between cachexia and systemic inflammation.[@CIT0010] We found that the NLR and PLR (for which a high value is associated with higher systemic inflammation) were both significantly higher in cachexia patients, in accordance with a study reporting that the preoperative NLR and PLR were useful predictors of postoperative survival in patients with stage I-II GC.[@CIT0011]

Cancer cachexia results not only from reduced nutrient intake or availability, but also from metabolic abnormalities triggered by the tumor, as well as by antineoplastic therapies. These factors stimulate systematic inflammation and cytokine networks[@CIT0012] that in turn result in significant loss of body weight, alterations in body composition, and declining physical function. Our findings showed that cachexia patients were more likely to be thinner, with a lower BMI; they also presented with less skeletal muscle, worse muscle function, and worse basic physical condition (higher ASA stage and CCI). Physical condition is a strong prognostic indicator of patient outcomes,[@CIT0013],[@CIT0014] as malnutrition and micronutrient deficiency can lead to the abnormal function of macrophages, neutrophils, and lymphocytes, which can inhibit the immune response,[@CIT0015] decrease response to anticancer therapy,[@CIT0016] and even increase the risk of tumor recurrence.[@CIT0017]

Similar to the results of other studies,[@CIT0007],[@CIT0018] the incidence of cachexia was higher in the elderly group. Considering that cachexia was significantly related to age and both cachexia and age were independent risk factors for OS, age and cachexia may interact with each other. Therefore, we subdivided the patients into four age groups and examined whether the correlation between cachexia and outcome was age-dependent. Interestingly, cachexia was a more effective risk factor for survival in the youngest group (younger than 50 years old; HR =4.947, *P*=0.029), and it was not significant in the oldest group (older than 70 years old; HR =1.411, *P*=0.119), which was quite different from the findings of previous studies.[@CIT0006],[@CIT0019] This may be explained by the fact that the interplay between chronic illness and elements such as malnutrition and immobility results in elderly patients being particularly vulnerable to cachexia. Additionally, considering the same diagnostic criteria and their better fundamental physical condition, younger cachexia patients may have better consumption than elderly cachexia patients. Moreover, cachexia only significantly affected postoperative length of stay and hospitalization costs in younger patients.

This is the first study to focus on cachexia in younger patients, and we found it to be a risk factor for prognosis in that group. We propose that more attention should be paid to improve the cachexia status in younger patients, as it will be more profitable in improving OS and decreasing length and costs of hospitalization. Fortunately, in recent years, data from some intervention studies have shown that cachexia could be potentially managed and reversed by multimodal interventions, including nutrition support, exercise, and drug therapy.[@CIT0020]--[@CIT0022]

This study has several limitations that should not be overlooked. First, all patients enrolled in our study were treated at two hospitals in Wenzhou, and bias in the population selection may be inevitable. Therefore, a large-scale multicenter trial is essential to verify our conclusion. Additionally, all the patients enrolled were Chinese,

The ethnic differences lead to significant differences in the results from the European and US patients. Second, the follow-up period in the present study is less than 5 years, and complete follow-up data need to be further acquired.

Conclusion {#S0005}
==========

In our prospective study, we found that cachexia was an independent risk factor for OS in GC patients. Additionally, cachexia could predict poor outcome in younger GC patients; therefore, greater attention should be paid to cachexia in younger patients.
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